Trigemina to Present Migraine Drug Data at Pain Therapeutics Summit East

MORAGA, CA, September 25, 2013 – Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, will be presenting clinical data for its leading drug candidate, TI-001, intranasal oxytocin, for the treatment of chronic migraine at the 7th Annual Pain Therapeutics Summit East, hosted by Arrowhead Publishers, September 25th-26th, 2013, in Boston, Massachusetts.

The presentation, titled, “Cytokine-driven Analgesic Efficacy of Nasal Oxytocin in the Treatment of Chronic Migraine,” will be delivered by David C. Yeomans, Ph.D., Chief Scientist and Founder of Trigemina, as well as the Director of Pain Research at Stanford University School of Medicine, on Thursday, September 26th at 8:55 AM ET. The presentation demonstrates that nasal application of oxytocin concentrates the distribution of the peptide to the pain-sensing trigeminal nerve, which produces a potent, but safe, analgesic effect. Additionally, Dr. Yeomans will be presenting data on the efficacy of TI-001 in reducing pain for chronic migraineurs.

“Previous studies have shown the release of calcitonin gene-related peptide (CGRP) by the trigeminal nerve neurons is likely critical to the pain experienced in episodic and chronic migraine patients, as well as in a number of other head pain conditions, especially those involving inflammation,” said Dr. Yeomans. “Fortunately, the increased levels of inflammatory mediators induces an increase in the number of receptors for oxytocin on trigeminal nerve cells, which when oxytocin binds with, reduces pain. Since chronic migraineurs have higher levels of inflammation, they also have more oxytocin receptors, making TI-001 highly effective in reducing their pain.”

TI-001 is currently being evaluated in a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study, titled TRIG-05, for efficacy, tolerability and safety in patients with chronic migraine. Promising preclinical and human pilot study results suggests TI-001 could be a safe, non-narcotic form of therapy for the effective relief of chronic migraine, a debilitating condition with few treatment options.

About Trigemina

Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina’s lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.

Contact:

The Ruth Group 
Aaron Estrada (media)
aestrada@theruthgroup.com
(646) 536-7028

Trigemina
Charles Yeomans
cyeomans@trigemina.com
(925) 377-0664

Comments are closed.